- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT02069990
Controlled, Randomized, Four-arm Comparative, Open Label, Multi-centric Clinical Trial to Compare the Efficacy and Safety Parameters of the Once-a-week or Once-a-month Administered 7000 IU, or 30000 IU Vitamin D (Cholecalciferol) to a 1000 IU Dosage Applied Daily in Vitamin D Deficient Patients
Circa-annual variations in 25-hydroxyvitamin D [25(OH)D] levels have been well established, and there also seems to be an effect of season on bone turnover and bone mass. been shown that bone turnover follows a circa-annual rhythm. On the basis of human clinical results, it was suggested that adipose tissue functions as a vitamin D buffering system that to a certain extent prevents uncontrolled synthesis of 25(OH)D in the liver. Directly related to this issue is the question of how much vitamin D is needed to ensure target serum 25-hydroxyvitamin D [25(OH)D] concentrations. According to the recommended dietary allowances, persons should achieve "levels of intake of essential nutrients considered to be adequate to meet the known nutritional needs of practically all healthy persons" Moreover it is important to note that the significant percentage of the population is temporarily of continuously deficient in vitamin D. In the similar condition of vitamin D deficiency, the aetiology is very different since only as almost exclusively as a consequence of a primary disease in children it is manifested: hypovitaminosis D is highly prevalent among children on renal substitution therapy, regardless of the type of therapy used and the stage of renal failure.
The rationale providing high dose strengths of vitamin D based on an assumption of better compliance especially in adult with senior age patients; also a potential for faster resolution of vitamin D deficiency, since utilization of cholecalciferol is higher when patients had low levels of 25(OH)D, and vice versa, there is a plateau phase when close to normal range (Vieth 2001).
According to clinical data, a doses equivalent of daily 1000 IU, (7000 IU per week, or 30000 IU per month) is considered as a minimal effective dose to treat vitamin D deficiency. The treatment of vitamin D with a duration of 30 days may result and increase of 6-12.5 nmol/L. With the deficiency criteria considered as <20 ng/ml, the vitamin supplementation is indicative, the treatment dosages should be adjusted to the increase planned to achieve the mid-normal range.
As the base of calculations, the doses of 40 IU results in an increase of 0.4 ng/ml in a period of 60 days. Accordingly 1000 IU in a period of 2-5 month resulted in an increase of approx 10 ng/ml. The risk of overdose in relatively low, since the absorption and the metabolic path is well controlled: automatic mechanisms downregulation at normal ranges.
In this study the there are three groups in the similar daily dose equivalent of 1000 IU/day. The absorption of daily , weekly and monthly dosing should have a buffered effect due to the body adipose tissues, balancing the daily 1,25(OH)D levels, and moreover to provide a biological reservoir. The three doses are considered as comparable in efficacy and safety.
The fourth group is intended to utilize the expanded dose range of 4286 IU/ day, using the 30.000 IU tablets on a weekly dosing schedule. This group is to demonstrate the efficacy of higher doses to normalize the vitamin D levels, within a reasonable timeframe of 60-90 days.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 3
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Budapest, Hungría, 1083
- Semmelweis University 1st Dept. of Int. Med-
-
Budapest, Hungría, 1084
- Ambulatory Dept of Józsefváros Health Services
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
Subject are included as 18 years or older ( adults) with the following specific criteria:
- 25(OH)D level < 50 nmol/L (20 ng/ml)
- female subjects either postmenopausal status or under proper (continuous) contraception during the course of the study are allowed to be enrolled
- Subject informed willing to participate and ICF signed and dated properly
Exclusion Criteria:
- hypercalcaemia/ se Ca levels out of 2.20-2.60 mmol/L range
- symptoms or lab results of elevated se Ca during the last year
- hypercalciuria within the last two years
- renal stones formation in anamnesis
- sever kidney disease ( CKD 3 or higher grade)
- chronic or serious illness that may result in malabsorption, the metabolisms of vitamin D or bones
- severe grade of metabolic diseases, bone disorders, excluded the primary age related osteoporosis,
- obesity ( BMI>35)
- diseases that resulted in changed absorption of calcium
- CHF or angina pectoris,
- recent (<3 month) surgical traumatic treatment
- alcohol or drug abuse,
- Vitamin D therapy or food supplements applied with the last 2 months, (at 1000 IU or above)
- planned travel (more than 5 days-long to a region of high natural UVB exposition)
- regular ( >2 per month) artificial UVB exposition (solarium)
- permanent use of non-permitted concomitant medication
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Comparador activo: 30000 IU cholecalcipherol once a week
30000 IU cholecalcipherol once a week oral
|
|
Experimental: 7000 IU cholecalcipherol once a week
7000 IU cholecalcipherol once a week oral
|
|
Experimental: 30000IU cholecalcipherol once a month
30000IU cholecalcipherol once a month oral
|
|
Comparador activo: 1000 IU cholecalciferol once a day
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Serum 25-OH-Vitamin-D level
Periodo de tiempo: 12 weeks
|
Based on the changes in 25(OH)D versus to baseline, in each group, and compared to the group of 1000 IU daily dosage applied. 1000 IU /day vs. 7000 IU/ week, eqv. 1000 IU/ day vs 30000 IU/ month egv. 1000 IU /day vs 30000 IU/week: superiority |
12 weeks
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
number of adverse events
Periodo de tiempo: 12 weeks
|
Frequency of adverse events for each group compared to group "A" ( as standard 1000 IU/day therapy).
Evaluation of adverse event includes patient reported symptoms and safety laboratory (seCa, seP, se creatinine, urinary Ca) abnormalities.
|
12 weeks
|
Serum PTH
Periodo de tiempo: 12 weeks
|
12 weeks
|
|
Urinary calcium
Periodo de tiempo: 12 weeks
|
12 weeks
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Peter Lakatos, professor, Semmelweis University
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- PAT12-730DS
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Deficiencia de vitamina D
-
University of UlsterDairy Council for Northern Ireland; Agri-food & Biosciences Institute; Center for...TerminadoConcentración de 25-hidroxivitamina D (estado de vitamina D)Reino Unido
-
Azienda Ospedaliera di BolzanoTerminadoMedición de 25(OH)D y deficiencia de 25(OH)D
-
University of UlsterNorthern Ireland Executive; HSC Public Health AgencyTerminadoEstado de la vitamina D | Concentración de vitamina DReino Unido
-
University College CorkTerminadoEstado de la vitamina D reflejado por la 25-hidroxivitamina D séricaIrlanda
-
Hospices Civils de LyonTerminado
-
University of Eastern FinlandTerminadoExpresión del gen diana del receptor de vitamina D | Concentración sérica de 25(OH)DFinlandia
-
Eiger BioPharmaceuticalsTerminado
-
Horopito LimitedAtlantia Food Clinical TrialsTerminado
-
University of Eastern FinlandDSM Nutritional Products, Inc.TerminadoExpresión del gen diana del receptor de vitamina D | Concentración sérica de 25(OH)DFinlandia
-
Eiger BioPharmaceuticalsAnkara UniversityTerminadoInfección crónica por hepatitis DPavo